Evidence map›Paper›PMID 25483486›Full record

ArticleHuman vaccines & immunotherapeutics2014

A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

Jay R McCoy, Janess M Mendoza, Kristin W Spik, Catherine Badger, Alan F Gomez, Connie S Schmaljohn, Niranjan Y Sardesai, Kate E Broderick

Open access · hybridAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jay R McCoya Inovio Pharmaceuticals Inc. ; Plymouth Meeting , PA USA.
Janess M Mendoza
Kristin W Spik
Catherine Badger
Alan F Gomez
Connie S Schmaljohn
Niranjan Y Sardesai
Kate E Broderick
Inovio Pharmaceuticals (United States) · USUnited States Army Medical Research Institute of Infectious Diseases · USUnited States Army Medical Research and Development Command · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of an effective and tolerable delivery method is a necessity for the success of DNA vaccines in the clinic. This manuscript describes the development and validation of a multi-headed intradermal electroporation device which would be applicable for delivering multiple DNA vaccine plasmids simultaneously but spatially separated. Reporter gene plasmids expressing green and red fluorescent proteins were used to demonstrate the impact of spatial separation on DNA delivery to increase the number of transfected cells and avoid interference through visible expression patterns. To investigate the impact of plasmid interference on immunogenicity, a disease target was investigated where issues with multi-valent vaccines had been previously described. DNA-based Hantaan and Puumala virus vaccines were delivered separately or as a combination and the effect of multi-valence was determined by appropriate assays. While a negative impact was observed for both antigenic vaccines when delivered together, these effects were mitigated when the vaccine was delivered using the multi-head device. We also demonstrate how the multi-head device facilitates higher dose delivery to the skin resulting in improved immune responses. This new multi-head platform device is an efficient, tolerable and non-invasive method to deliver multiple plasmid DNA constructs simultaneously allowing the tailoring of delivery sites for combination vaccines. Additionally, this device would allow the delivery of multi-plasmid vaccine formulations without risk of impacted immune responses through interference. Such a low-cost, easy to use device platform for the delivery of multi-agent DNA vaccines would have direct applications by the military and healthcare sectors for mass vaccination purposes.

Indexed as

Administration, CutaneousAnimalsAntibodies, ViralCricetinaeDrug Delivery SystemsElectroporationGenes, ReporterGreen Fluorescent ProteinsGuinea PigsHantaan virusHemorrhagic Fever with Renal SyndromeInjections, IntradermalLuminescent ProteinsPlasmidsPuumala virusRed Fluorescent ProteinAntibodies, ViralGreen Fluorescent ProteinsLuminescent ProteinsRed Fluorescent ProteinVaccines, DNAViral VaccinesdermalDNA vaccineelectroporationmulti-agentnoninvasivetolerable

Identifiers

PMID25483486
PMCPMC5443063
OpenAlexW4251751409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.